Tyr281
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.6
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr281  -  TREML1 (human)

Site Information
VCSKPVTyATVIFPG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454865

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 ) , mutation of modification site ( 3 ) , western blotting ( 3 )
Disease tissue studied:
leukemia ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 1 ) , platelet-blood ( 1 ) , RBL-2H3 (basophil) ( 3 ) , T lymphocyte-blood ( 2 )

Upstream Regulation
Treatments:
antibody ( 2 ) , H2O2 ( 1 )

Downstream Regulation
Effects of modification on TREML1:
molecular association, regulation ( 3 )
Effects of modification on biological processes:
signaling pathway regulation ( 3 )
Induce interaction with:
SHIP-2 (human) ( 3 )

References 

1

Schmoker AM, et al. (2020) Defining the TLT-1 interactome from resting and activated human platelets. J Proteomics 215, 103638
31923473   Curated Info

2

Ruperez P, Gago-Martinez A, Burlingame AL, Oses-Prieto JA (2012) Quantitative phosphoproteomic analysis reveals a role for serine and threonine kinases in the cytoskeletal reorganization in early T cell receptor activation in human primary T cells. Mol Cell Proteomics 11, 171-86
22499768   Curated Info

3

Barrow AD, et al. (2004) Cutting edge: TREM-like transcript-1, a platelet immunoreceptor tyrosine-based inhibition motif encoding costimulatory immunoreceptor that enhances, rather than inhibits, calcium signaling via SHP-2. J Immunol 172, 5838-42
15128762   Curated Info